FDA PMA FDA Class 2 Approved 🇺🇸 United States

Prostate-Specific Antigen (Psa) For Management Of Prostate Cancers

PMA: P000027 · Supplement: S023 · Decision Mar 2, 2017
Classifications
1
FEI Numbers
37
Registration Numbers
37

Basic Information

Device Name
Prostate-Specific Antigen (Psa) For Management Of Prostate Cancers
Trade Name
Elecsys free PSA, free PSA Calset, free PSA CalCheck
PMA Number
P000027
Supplement Number
S023
Device Class
FDA Class 2
Product Code
LTJ
Generic Name
PROSTATE-SPECIFIC ANTIGEN (PSA) FOR MANAGEMENT OF PROSTATE CANCERS
Regulation Number
866.6010
Medical Specialty
Immunology
Advisory Committee
Immunology
Decision
Approved
Decision Code
APPR
Decision Date
March 2, 2017
Date Received
September 7, 2016
Supplement Type
Normal 180 Day Track No User Fee
Supplement Reason
Labeling Change - Indications/instructions/shelf life/tradename
Expedited Review
N

Advisory Committee Statement

Approval for a modification to the proprietary device names.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
LTJ Prostate-Specific Antigen (Psa) For Management Of Prostate Cancers